Bangalore-based Strides Arcolab is looking for buyers for its business in the Japanese market. Strides has given a mandate to Daiwa Capital to scout for buyers from the East Asian nation. The Rs 1,700-crore Strides had earlier appointed US-based Jefferies to identify buyers from all other global markets, except Japan. Although Strides has plans to sell its pharma and branded generic business that fetches it a revenue of Rs 1,075 crore, the company will retain its other business — injectables. It is a Rs 690-crore business. The reason behind the company’s decision to retain injectables includes its pacts with leading players like Pfizer. In early 2010, Strides entered into a licensing and supply agreement with Pfizer for a portfolio of 40 off-patent sterile injectables and oral products.
The company had reduced its debt equity ration to 1.57 in FY 2010 from 4.63 in FY 2007. The company has sales of Rs 780 crore from the branded generics business. Out of the branded generic sales, Australia-subsidiary Ascent Pharmahealth contributes a revenue of Rs 583 crore, African business contributes about Rs 137 crore and India has a sales of Rs 60 crore. Strides has manufacturing facilities for branded generic drugs each in Singapore, Lagos, Milan and three in India.
The government-funded National Health Insurance scheme covers Japanese citizens. The government, which wanted to reduce the burden, is looking to expand generic drug penetration to 30 per cent of the overall market by 2012. The $75-billion Japanese drug market has a small generic segment, worth 5 per cent of the total in value terms and 19 per cent in volume terms. Last year, Strides rebranded its injectable business as Agila and it had signed an agreement with BioChimico of Brazil to set up a joint venture company for the Brazilian hospital market.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1807.85 |
| Dr. Reddys Lab | 1341.65 |
| Cipla | 1470.45 |
| Lupin | 2155.95 |
| Zydus Lifesciences | 969.75 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
